118 related articles for article (PubMed ID: 1020253)
21. [Immunological aspects of melanoma].
Sjögren H
Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
[No Abstract] [Full Text] [Related]
22. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
23. [Immunologic response in patients with melanoma of the skin].
Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
[TBL] [Abstract][Full Text] [Related]
24. [Standardized recall antigen testing in patients with malignant melanoma, endogenous eczema patients and healthy humans].
Stenger D; Delbrück H; Krumrey K; Zaun H
Z Hautkr; 1983 Mar; 58(5):293-304. PubMed ID: 6845797
[TBL] [Abstract][Full Text] [Related]
25. Immunological mechanisms in choroidal melanoma.
Char DH
Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):389-93. PubMed ID: 273995
[TBL] [Abstract][Full Text] [Related]
26. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
Takahashi T; Irie RF; Morton DL; Hoon DS
Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
[TBL] [Abstract][Full Text] [Related]
27. Cell-mediated immunity against malignant melanoma in monozygous twins.
Nagel GA; St Arneault G; Holland JF; Kirkpatrick D; Kirkpatrick R
Cancer Res; 1970 Jun; 30(6):1828-32. PubMed ID: 5466283
[No Abstract] [Full Text] [Related]
28. [State of the stroma in melanoma in patients with different delayed hypersensitivity reaction to neoplasm antigen].
Lavnikova GA; Voronina EA; Babakova SV
Vopr Onkol; 1978; 24(11):24-30. PubMed ID: 741696
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
30. [Immunology of malignant melanoma].
Bourgoin JJ
Ann Inst Pasteur (Paris); 1972 Apr; 122(4):789-807. PubMed ID: 4559237
[No Abstract] [Full Text] [Related]
31. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
32. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
33. [Changes in certain immunological parameters in patients with malignant skin melanoma].
Lukács L; Bárdosi L; Somos Z; Kocsis B
Orv Hetil; 1985 Apr; 126(14):819-26. PubMed ID: 3873050
[No Abstract] [Full Text] [Related]
34. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies to human melanoma-associated antigens: an amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody, and immune complexes.
Morgan AC; McIntyre RF
Cancer Res; 1983 Jul; 43(7):3155-9. PubMed ID: 6850625
[TBL] [Abstract][Full Text] [Related]
36. [Current developments concerning malignant skin melanoma].
Dargent M
Maroc Med; 1972 Oct; 52(561):571-86. PubMed ID: 4667467
[No Abstract] [Full Text] [Related]
37. Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma.
Hollinshead AC
Cancer; 1975 Oct; 36(4):1282-8. PubMed ID: 51680
[TBL] [Abstract][Full Text] [Related]
38. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
39. [Study of the intracytoplasmatic antigens of malignant melanoma cells. Preliminary report].
De Moragas J; Anguera A; Viñas J
Actas Dermosifiliogr; 1971; 62(9):429-32. PubMed ID: 4949557
[No Abstract] [Full Text] [Related]
40. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
